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incorporated glutamine (10 gm po TID starting with t e adminis- 
tration of the preparative regimen) standardly for mucositis pro- 
phylaxis. Twenty-four patients received glutamine. Eleven 
patients were lost to follow up (6 no glutamine, 5glutamine). The 
response rate to transplant in the no glutamine group was 43%, 
compared with 47% in the glutamine group. In the no glutamine 
group, 8/11 patients (73%) were progression free at a median fol- 
low-up of 19 months, compared with i5/19 (79%) in the gfuta- 
mine group at a median follow-up of only 9 months. Interestingly, 
of the patients who relapsed, the median time to relapse was 17 
months in the no glutamine group and only 6 months in the gluta- 
mine group. Our observation is that glutamine at this dose may be 
associated with early relapse and poorer progression-free survival 
(PFS) in MNI patients treated with high-dose melphalan. These 
data support he iTl vitro examination of glutamine in tumor cell 
lines to discern if glutamine abrogates the cytotoxic effects of 
chemotherapy. Future prospective trials should scrutinize 
response rates, PFS, and overall survival in glutamine and non- 
glutamine treated patients especially if higher-doses are utilized. 
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Background: Previous chemotherapy, radiation and bone marrow 
infiltration by malignancy are predictors of poor stem cell yield in 
patients undergoing peripheral blood stem cell harvests for autolo- 
gous stem cell transplantation (SCT). Prior treatment with Fludara- 
bine is thought to adversely affect yields as well. We have examined 
our institution's data to determine whether this is an accurate obser- 
vation. Methods: Apheresis records from patients with Non- 
Hodgkins Lymphoma (NHL) undergoing SCT were reviewed 
(N=43). The patient population ncluded 35 patients who received 
non-fludarabine containing chemotherapy regimens; with 4 patients 
of the non-fludarabine population receiving radiation and 
chemotherapy. Eight (8) patients had received chemotherapy that 
included 3 to 6 cycles of FND (average 3.8). Patients were uniform- 
ly mobilized with 10mcg/kg/d of Granulocyte Colony Stimulating 
Factor (G-CSF). High volume (40L) apheresis was performed for 1- 
4 days with a collection goal of 5 X10^6 CD34/kg ideal body 
weight. Data were analyzed using non-parametric one-way analyses 
of variance. Results: Patients who had received previous chemother- 
apy with no fludarabine yielded a median of 5.8 XI0^6 CD34 cells 
(n=31; range 2.7-11.6 X10A6). Patients who had previously received 
three to six cycles of FND were also able to meet he apheresis goal 
for collection, yielding a median of 5.0 XIOA6 CD34 cells/kg (n=8; 
range 4-13.1 X10^6). Patients who had received prior non-fludara- 
bine chemotherapy and radiation were not generally abIe to meet 
the apheresis target, and had the lowest median yield of CD34 cells, 
(3.1 XIOA6 CD 34 cells/kg; n=4; range 0.9-5 X10A6). Conclusion: 
Pretreatment with 6 or fewer cycles of FND had no statistically sig- 
nificant adverse ffect on the total yield of CD34 cells. Patients 
treated with FND did not require additional apheresis procedures, 
as compared to non-fludarabine regimen treated patients. As expect- 
ed, increased cycles of prior chemotherapy, prior radiation, and 
increasing age were all associated with lower total CD34 yields and 
additional apheresis procedures in order t0.reach the target dose. 
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Todays health care cltinate and advancements in Blood and 
Marrow Transplantation have challenged the outpatient adminis- 
trative staff to develop innovative strategies in caring for higher 
acuity patients. Autologus Transplantation patients are frequently 
discharged from the hospital immediately following chemotherapy 
for mobilization, or soon after engraftment. The challenge was to 
integrate this patient population into the outpatient clinic. These 
early discharges challenge the outpatient staff to provide quality 
care while meeting the needs of all patients. The rationale for the 
development of the Fast Track Clinic is to perform laboratory 
testing and patient evaluation by a bone marrow transplant urse, 
APN, and clinical pharmacist in a familiar environment. Specifi- 
cally identified treatment eeds are performed in this clinical area 
while long-term fluid infusion, and blood product ransfllsion are 
transitioned to other clinical areas. The Administrative challenges 
in developing this clinical area, included space feasibility, room 
utilization, staff education/skills, equipment/supply issues, finan- 
cial issues, and staff buy-in. Space feasibility was evaluated by a 
room utilization study indicating low usage in the morning hours. 
The staff educator provided intense training on pump usage, CVC 
care, and IV drug administration. Strategies were planned in col- 
laborative multidisciplinary meetings with the administrative and 
clinical staff to provide a sense of ownership in developing this 
process. One advantage of the fast track clinic is that patients are 
followed by the same personnel from initial consultation through- 
out the transplant journey. Another impact of the implementation 
of the fast track clinic is the enhancement of the RNs technical, 
critical thinking, and problem solving skills. Patient satisfaction 
surveys and comment cards are obtained on a monthly basis, 
reviewed for possible improvements, and demonstrate a high level 
of satisfaction regarding care of the patient. 
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The use of Rituximab for post-transplant immunolnodulation 
has revealed promising effects. Published ata demonstrates that 
administration of Rituximab following autologous peripheral 
stem cell transplant causes rapid depletion of CD20+ cells with- 
out increase in infection. Studies conducted in patients with fol- 
licular lymphoma nd mantle cell lymphoma suggest hat this 
approach is feasible and safe, and appears effective in eliminat- 
ing minimal residual disease leading to high rates of durable 
remission. Common reported side effects associated with Ritux- 
imab administration i clude fever and chills, bronchospasm, 
angioedema, hypersensitivity reactions a d tmnor lysis syn- 
drome. Transient cytopenias are usually not severe. Less com- 
mon adverse events include hypogammaglobulinemia, cardiac 
arwthmias, grade 4 cytopenias, serum sickness and vasculitis. 
The infusion of the antibody during immune reeonstitution 
after autograft may be associated with adverse vents not cmn- 
monly seen in the pre-transplant setting. We reviewed 7 
patients who received Rituximab consolidation following 
APSCT and documented the incidence of cytopenias and any 
associated adverse events. Two patients had APSCT for trans- 
formed follicular lymphoma, tour patients had diffuse large cell 
lymphoma nd one had mantle cell lymphoma. Adverse events 
included prolonged thrombocytopenia and neutropenia and one 
patient developed acute congestive heart failure with diffuse 
myocardial hypokinesis and severe tricuspid regurgitation 
reversible after treatment with steroids and inotropes. Five 
patients are in complete remission with a median follow up of 
45 weeks and two patients recurred shortly after completing Rit- 
u~mab consolidation. The administration of Rituximab follow- 
i ng APSCT may be associated with improved progression-free 
survival and appears to be feasible with careful observation. 
Based on this retrospective r view we suspect hat the adminis- 
tration of Rituximab in the post-transplant setting may be asso- 
ciated with uncommon and serious side effects such as acute 
heart failure and moderate to severe thronthocytopenia and neu- 
tropenia observed even after complete count recovery post- 
transplant. 
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